The HPV vaccine program for cervical cancer was introduced in England in 2008, which showed a substantial reduction in cases by around 87% to those who received it at ages 12-13.
Some oropharyngeal cancer is linked to human papillomavirus (HPV), wherein 3,500 new cases in women and 16,200 cases in men are diagnosed each year. The new therapeutic technology of Mayo Clinic could treat patients with HPV-associated oral cancer with fewer side effects than the current standard treatment.